Brought to you by 
Idorsia gets share of ponesimod and cadazolid revenues from Actelion
21 May 2020
Executive Summary
Idorsia Pharmaceuticals Ltd. entered a revenue sharing agreement with Actelion Pharmaceuticals Ltd., from which it spun off earlier this year. The arrangement relates to Actelion's ponesimod and cadazolid, which were not included in the discovery operations and certain early clinical development assets Actelion previously divested to Idorsia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Idorsia gets share of ponesimod and cadazolid revenues from Actelion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice